Table 1.
ROR1-targetd therapies in clinical trials.
| Drug | Description | Disease | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Cirmtuzumab | mAb | CLL MCL Breast cancer |
NCT03088878 NCT02776917 NCT02222688 NCT02860676 |
| VLS-101 | ADC (MMAE) |
Lung cancer Breast cancer Hematological neoplasms |
NCT03833180 NCT04504916 |
| NBE-002 | ADC (PNU-159682) |
Triple Negative Breast Cancer Advanced Solid Tumor |
NCT04441099 |
| NVG-111 | Bispecific antibody to ROR1 and CD3 | CLL MCL |
NCT04763083 |
| CAR-T | CAR-T | Lung cancer Breast cancer Hematological neoplasms |
NCT02706392 |
ADC, antibody drug conjugate; CLL, chronic lymphocytic leukemia; mAb, monoclonal antibody; MCL, mantle cell lymphoma; MMAE, Monomethyl auristatin E.